RAF265 (CHIR-265)

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：RAF265 (CHIR-265)	Purity：98% min
CAS NO：927880-90-8	Solubility：DMSO : ≥ 26 mg/mL (50.15 mM)
Molecular Formula：C₂₄H₁₆F₆N₆O	Package：Package according to customer requirements
Molecular Weight：518.414	Storage：Store at -20℃

Quality control

Remarks

CHIR-265 is an orally bioavailable small molecule with potential antineoplastic activity.CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms. 5).

Raf Inhibitors Related Products:

Vemurafenib; PLX-4720; Debrafenib; Regorafenib; GDC-0879; AZ-628; SB590885; ZM 336372; TAK-632; B-Raf IN 1; AZ304; Dabrafenib Mesylate; RAF709; LY3009120; RO5126766; Doramapimod; MLN2480 ; GW5074

References

[1]. AACR Meeting Abstracts 2008;2008:4876.

[2]. Mordant P, et al. Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther, 2010, 9(2), 358-368.